Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis-Reference-Cited by-同舟云学术

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis

Published:2016-05 Issue:5 Volume:4 Page:381-389
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Kreuter Michael,Wuyts Wim,Renzoni Elisabetta,Koschel Dirk,Maher Toby M,Kolb Martin,Weycker Derek,Spagnolo Paolo,Kirchgaessler Klaus-Uwe,Herth Felix J F,Costabel Ulrich

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference26 articles.

1. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am J Respir Crit Care Med,2011

2. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials;Noble;Lancet,2011

3. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis;King;N Engl J Med,2014

4. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis;Richeldi;N Engl J Med,2014

5. Guidelines for the diagnosis and management of gastroesophageal reflux disease;Katz;Am J Gastroenterol,2013

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of the 2022 American Thoracic/European Respiratory Society/Japanese Respiratory Society/Associatión Latinoamericana de Tórax (ATS/ERS/JRS/ALAT) idiopathic pulmonary fibrosis and progressive pulmonary fibrosis clinical practice guideline to a Canadian population: An opinion piece;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2024-07-03

2. The Role of Proton Pump Inhibitors in the Realm of Idiopathic Pulmonary Fibrosis and its Associated Comorbidities: A Systematic Review;Cureus;2024-03-11

3. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision;Respirology;2024-01-11

4. Gastroesophageal reflux disease and idiopathic pulmonary fibrosis risk: A mendelian randomization study;European Journal of Inflammation;2024-01

5. Progress in Drug Therapy for Idiopathic Pulmonary Fibrosis;Advances in Clinical Medicine;2024